Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum
tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.